Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities
Net loss	$ (7,704,636)	$ (2,495,525)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense	1,225	1,224
Research and development-acquired license, expensed	95,000	132,164
Stock issued for research and development		36,000
Stock-based compensation	2,495,219	143,053
Unrealized gain on marketable securities	(3,664)
Changes in assets and liabilities:
Prepaid expenses	(97,716)	(12,356)
Accrued salaries and benefits		(1,542)
Accounts payable	267,357	94,356
Net cash used in operating activities	(4,947,215)	(2,102,626)
Cash flows from investing activities
Purchase of marketable securities	(800,000)
Purchase of research and development licenses	(95,000)
Net cash used in investing activities	(895,000)
Cash flows from financing activities
Proceeds from issuance of Series A Convertible Preferred Stock and warrants for cash in an offering, net		1,186,320
Proceeds from issuance of common stock in the IPO, net of offering cost	5,840,167
Proceeds from issuance common stock and warrants, net of offering cost	1,610,130
Proceeds from exercise of warrants	163
Payment of employee withholdings for vested restricted stock		(31,513)
Net cash provided by financing activities	7,450,460	1,154,807
Net increase (decrease) in cash	1,608,245	(947,819)
Cash and restricted cash, beginning of year	282,621	1,230,440
Cash and restricted cash, end of year	1,890,866	282,621
Non-cash investing and financing activities
Conversion of preferred stock to common stock upon completion of the IPO	310
Common stock issued for acquired license		132,164
Cashless warrant exercise	22
Offering cost included in accrued expenses	$ 30,484	$ 206,671